Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations

WHAT:

Eli Lilly and Company (NYSE: LLY) will announce a multi-million dollar expansion to the company's Indianapolis insulin manufacturing operations. The expanded facilities, which will manufacture high-tech insulin cartridges to meet the growing U.S. diabetes demand, represents the first increase in the company's Indianapolis manufacturing operations in more than two decades.



WHO:

Local and state government officials, including Indianapolis Mayor Greg Ballard and Lt. Governor Becky Skillman, will join officials from Lilly.



WHEN:

9 a.m. Thursday, November 1



WHERE:

Lilly Technology Center, 1555 S. Harding Street. From downtown, media should drive southwest on Kentucky Avenue to the intersection at Morris Street. Turn right on Morris Street. Continue on Morris Street to Harding Street.  Take a left on Harding Street and go approximately 1 mile to the main Lilly Technology Center entrance, which is on the left side of the road.  Security will direct you to the ceremonies. Parking is available at the site.




Important: Lilly will provide an online live stream of the press conference at its corporate web site, www.lilly.com  A link to the live stream will appear on the front page of the web site.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.  

Refer to: (317) 277-4021 – Greg Kueterman; [email protected] 
               (317) 433-9899 – Edward Sagebiel; [email protected]

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

/PRNewswire -- Oct. 30/

SOURCE Eli Lilly and Company

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.